Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Axsome Therapeutics, Inc. clinical trials
The registry lists 37 studies whose lead sponsor is Axsome Therapeutics, Inc.. 12 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 13, 2026.
Keep track of what changes. Save the Axsome Therapeutics, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Axsome Therapeutics, Inc..
- Axsome Therapeutics, Inc.37 studiesSame company
Something wrong?
Focus areas
Conditions Axsome Therapeutics, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 37 of 37.
- Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)RecruitingNCT07717879Phase 3
- Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)RecruitingNCT07717892Phase 3
- Open-Label Safety Study of AXS-14 in Subjects With FibromyalgiaEnrolling by invitationNCT07637162Phase 3
- Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using SolriamfetolRecruitingNCT07484217Phase 3
- Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)RecruitingNCT07766655Phase 3
- An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHDEnrolling by invitationNCT07773883Phase 3
- SUNOSI® (Solriamfetol) Pregnancy RegistryRecruitingNCT06413420
- Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research DesignRecruitingNCT07398417Phase 3
- A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating DisorderEnrolling by invitationNCT06878976Phase 3
- Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using SolriamfetolRecruitingNCT06413433Phase 3
- Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)RecruitingNCT06568367Phase 3
- A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive SymptomsRecruitingNCT06223880Phase 4
- A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease AgitationCompletedNCT05557409Phase 3
- An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension StudyTerminatedNCT06736509Phase 3
- Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)CompletedNCT03881852Phase 2
- A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With NarcolepsyCompletedNCT05059223Phase 3
- A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)CompletedNCT05972044Phase 3
- Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)TerminatedNCT04634669Phase 2
- Initiating Early Control of Migraine Pain and Associated SymptomsCompletedNCT04163185Phase 3
- Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled StudyCompletedNCT04789174Phase 4
- Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using SolriamfetolCompletedNCT06360419Phase 3
- A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease AgitationCompletedNCT04947553Phase 3
- Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)CompletedNCT05550207Phase 3
- A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)CompletedNCT05113745Phase 3
- Assessing Clinical Outcomes in Alzheimer's Disease AgitationCompletedNCT04797715Phase 3
- Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)CompletedNCT04068051Phase 3
- Addressing Dementia Via Agitation-Centered EvaluationCompletedNCT03226522Phase 2/3
- Maximizing Outcomes in Treating Acute MigraineCompletedNCT03896009Phase 3
- Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral AdministrationCompletedNCT05008341Phase 1
- A Trial of AXS-05 in Patients With Major Depressive DisorderCompletedNCT04019704Phase 3
- Open-Label Safety Study of AXS-05 in Subjects With DepressionCompletedNCT04039022Phase 3
- Mechanistic Evaluation of Response in TRD (MERIT)CompletedNCT04608396Phase 2
- Assessing Symptomatic Clinical Episodes in DepressionCompletedNCT03595579Phase 2
- An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent PatientsStatus unknownNCT04971291Phase 2
- A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive DisorderCompletedNCT02741791Phase 3
- A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow LesionsStatus unknownNCT02746068Phase 3
- CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1Status unknownNCT02504008Phase 3